Fluctuations of Epstein-Barr Virus Serological Antibodies and Risk for Nasopharyngeal Carcinoma: A Prospective Screening Study with a 20-Year Follow-Up

Background The impact of variation of Epstein-Barr virus (EBV) antibody titers before the development of nasopharyngeal carcinoma (NPC) is still unclear. We analyzed the fluctuations of antibodies against EBV before histopathological diagnosis to assess the risk of NPC and aimed to provide a reliable basis for screening in high risk populations. Methods This study was based on a population-based screening program in Sihui County in Guangdong Province of China. A total of 18,986 subjects were recruited in 1987 and 1992, respectively. Baseline and repeated serological tests were performed for IgA antibodies against EBV capsid antigen (VCA/IgA) and early antigen (EA/IgA). Follow-up until the end of 2007 was accomplished through linkage with population and health registers. Cox proportional hazards regression model was used to estimate the relative risk of NPC in association with EBV antibodies. Time-dependent receiver operating characteristic curve (ROC) analysis was used to further evaluate the predictive ability. Results A total of 125 NPCs occurred during an average of 16.9 years of follow-up. Using baseline information alone or together with repeated measurements, serological levels of VCA/IgA and EA/IgA were significantly associated with increased risks for NPC, with a striking dose-response relationship and most prominent during the first 5 years of follow-up. Considering the fluctuant types of serological titers observed during the first three tests, relative risk was highest among participants with ascending titers of EBV VCA/IgA antibodies with an adjusted hazard ratio (HR) of 21.3 (95% confidence interval [CI] 7.1 to 64.1), and lowest for those with decreasing titers (HR = 1.5, 95% CI 0.2 to 11.4), during the first 5 years of follow-up. Time-dependent ROC analysis showed that VCA/IgA had better predictive performance for NPC incidence than EA/IgA. Conclusion Our study documents that elevated EBV antibodies, particularly with ascending titers, are strongly associated with an increased risk for NPC.

[1]  X. An,et al.  Plasma Epstein‐Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy , 2011, Cancer.

[2]  S. Haryana,et al.  Humoral immune responses to Epstein–Barr virus encoded tumor associated proteins and their putative extracellular domains in nasopharyngeal carcinoma patients and regional controls , 2011, Journal of medical virology.

[3]  S. Kondo,et al.  Epstein-Barr Virus latent membrane protein 1 induces Snail and epithelial–mesenchymal transition in metastatic nasopharyngeal carcinoma , 2011, British Journal of Cancer.

[4]  Wancai Yang,et al.  EBV-encoded LMP1 increases nuclear β-catenin accumulation and its transcriptional activity in nasopharyngeal carcinoma , 2011, Tumor Biology.

[5]  N. Raab-Traub,et al.  Epstein-Barr Virus LMP1 Activates EGFR, STAT3, and ERK through Effects on PKCδ , 2011, Journal of Virology.

[6]  C. Qian,et al.  The prevalence and prevention of nasopharyngeal carcinoma in China , 2011, Chinese journal of cancer.

[7]  Chien-Jen Chen,et al.  Familial tendency and risk of nasopharyngeal carcinoma in taiwan: effects of covariates on risk. , 2011, American journal of epidemiology.

[8]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[9]  Mhairi A. Morris,et al.  Role of the Epstein-Barr virus-encoded latent membrane protein-1, LMP1, in the pathogenesis of nasopharyngeal carcinoma. , 2009, Future oncology.

[10]  A. Khabir,et al.  IgA antibodies against the Epstein‐Barr nuclear antigen1 as a valuable biomarker for the diagnosis of nasopharyngeal carcinoma in Tunisian patients , 2009, Journal of medical virology.

[11]  F. Marincola,et al.  HLA associations with nasopharyngeal carcinoma. , 2009, Current molecular medicine.

[12]  Chien-Jen Chen,et al.  Independent Effect of EBV and Cigarette Smoking on Nasopharyngeal Carcinoma: A 20-Year Follow-Up Study on 9,622 Males without Family History in Taiwan , 2009, Cancer Epidemiology Biomarkers & Prevention.

[13]  T. Matsuda,et al.  Comparison of time trends in prostate cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, Vols IV-IX. , 2008, Japanese journal of clinical oncology.

[14]  T. Sobue,et al.  Comparison of time trends in cancer incidence (1973-2002) in Asia, from Cancer Incidence in Five Continents Vols IV-IX. , 2008, Japanese journal of clinical oncology.

[15]  J. Tang,et al.  Evaluation of Epstein-Barr virus antigen-based immunoassays for serological diagnosis of nasopharyngeal carcinoma. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[16]  S. Haryana,et al.  Native early antigen of Epstein–Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma , 2007, Journal of medical virology.

[17]  Yi Yu,et al.  Sustained elevation of Epstein–Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma , 2007, British Journal of Cancer.

[18]  K. Katanoda,et al.  Comparison of time trends in cancer incidence (1973-1997) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vol. IV-VIII. , 2007, Japanese journal of clinical oncology.

[19]  H. Adami,et al.  The Enigmatic Epidemiology of Nasopharyngeal Carcinoma , 2006, Cancer Epidemiology Biomarkers & Prevention.

[20]  H. Adami,et al.  Trends in incidence and mortality of nasopharyngeal carcinoma over a 20–25 year period (1978/1983–2002) in Sihui and Cangwu counties in southern China , 2006, BMC Cancer.

[21]  Tianxi Cai,et al.  Application of the Time‐Dependent ROC Curves for Prognostic Accuracy with Multiple Biomarkers , 2006, Biometrics.

[22]  Kwok-Hung Chan,et al.  Epstein-Barr virus serology in early detection and screening of nasopharyngeal carcinoma. , 2006, Ai zheng = Aizheng = Chinese journal of cancer.

[23]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[24]  J. Sham,et al.  EBV specific antibody‐based and DNA‐based assays in serologic diagnosis of nasopharyngeal carcinoma , 2003, International journal of cancer.

[25]  Jian-Min Yuan,et al.  Epidemiology of nasopharyngeal carcinoma. , 2002, Seminars in cancer biology.

[26]  N. Raab-Traub.  Epstein-Barr virus in the pathogenesis of NPC. , 2002, Seminars in cancer biology.

[27]  K. Lo,et al.  Genetic and epigenetic changes in nasopharyngeal carcinoma. , 2002, Seminars in cancer biology.

[28]  Yan Fang,et al.  Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4 , 2002, Nature Genetics.

[29]  J. Martínez-Montero,et al.  Association of Epstein-Barr Virus and Nasopharyngeal Carcinoma in Caucasian Patients , 2002, The Annals of otology, rhinology, and laryngology.

[30]  C. J. Chen,et al.  Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. , 2001, The New England journal of medicine.

[31]  G. Niedobitek.  Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma , 2000, Molecular pathology : MP.

[32]  T. Lumley,et al.  Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.

[33]  Jian-Min Yuan,et al.  Preserved foods in relation to risk of nasopharyngeal carcinoma in Shanghai, China , 2000, International journal of cancer.

[34]  Tai-fu Liu,et al.  Issues in the management of nasopharyngeal carcinoma. , 1999, Critical reviews in oncology/hematology.

[35]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[36]  G. Niedobitek,et al.  Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. , 1996, Seminars in cancer biology.

[37]  E. Kremmer,et al.  IN SITU DETECTION OF THE EPSTEIN–BARR VIRUS‐ENCODED NUCLEAR ANTIGEN 1 IN ORAL HAIRY LEUKOPLAKIA AND VIRUS‐ASSOCIATED CARCINOMAS , 1996, The Journal of pathology.

[38]  N. Day,et al.  Preserved foods and nasopharyngeal carcinoma: A case‐control study among singapore chinese , 1994, International journal of cancer.

[39]  G. Eklund,et al.  EPSTEIN-BARR VIRUS INFECTION, SALTED FISH AND NASOPHARYNGEAL CARCINOMA , 1994 .

[40]  G. Eklund,et al.  Epstein-Barr virus infection, salted fish and nasopharyngeal carcinoma. A case-control study in southern China. , 1994, Acta oncologica.

[41]  Q Y Yao,et al.  Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts , 1992, Journal of virology.

[42]  U. Prasad,et al.  Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. , 1992, The American journal of pathology.

[43]  Q. Yao,et al.  Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism. , 1992, Science.

[44]  J. Sham,et al.  Immunoglobulin A against viral capsid antigen of Epstein‐Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma , 1992, Cancer.

[45]  H. Stein,et al.  Epstein–Barr virus and carcinomas: Undifferentiated carcinomas but not squamous cell carcinomas of the nasopharynx are regularly associated with the virus , 1991, The Journal of pathology.

[46]  N. Day,et al.  Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA regions , 1990, Nature.

[47]  D. Choy,et al.  In situ detection of Epstein-Barr virus markers in nasopharyngeal carcinoma patients. , 1989, Oncology.

[48]  T. Tursz,et al.  Epstein-Barr virus gene expression in nasopharyngeal carcinoma. , 1988, The Journal of general virology.

[49]  B. Henderson,et al.  Preserved foods and nasopharyngeal carcinoma: a case-control study in Guangxi, China. , 1988, Cancer research.

[50]  A. Huang,et al.  The differentiated form of nasopharyngeal carcinoma contains epstein‐barr virus DNA , 1987, International journal of cancer.

[51]  B. Henderson,et al.  Intake of Cantonese-style salted fish as a cause of nasopharyngeal carcinoma. , 1987, IARC scientific publications.

[52]  J. M. Zhang,et al.  Epstein-Barr virus seroepidemiology in China. , 1986, AIDS research.

[53]  B. Henderson,et al.  Cantonese-style salted fish as a cause of nasopharyngeal carcinoma: report of a case-control study in Hong Kong. , 1986, Cancer research.

[54]  E. Kieff,et al.  Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies , 1983, Journal of virology.

[55]  L. Y. Li,et al.  Follow-up studies on Epstein-Barr virus IgA/VCA antibody-positive persons in Zangwu County, China. , 1983, Intervirology.

[56]  David A. Schoenfeld,et al.  Partial residuals for the proportional hazards regression model , 1982 .

[57]  Yu Wang,et al.  Serological mass survey for early detection of nasopharyngeal carcinoma in wuzhou city, china , 1982, International journal of cancer.

[58]  G. Bornkamm,et al.  Association of Epstein‐Barr virus with nasopharyngeal carcinoma in alaskan native patients: Serum antibodies and tissue EBNA and DNA , 1981, International journal of cancer.

[59]  W. Henle,et al.  Nasopharyngeal carcinoma in alaskan eskimos, indians, and aleuts: A review of cases and study of epstein‐barr virus, HLA, and environmental risk factors , 1980, Cancer.

[60]  T. Bender,et al.  Epstein‐Barr virus‐specific antibody titers in seven Alaskan Natives before and after diagnosis of nasopharyngeal carcinoma , 1980, International journal of cancer.

[61]  Z. Jisong,et al.  Application of an immunoenzymatic method and an immunoautoradiographic method for a mass survey of nasopharyngeal carcinoma. , 1980, Intervirology.

[62]  W. Henle,et al.  Epstein‐barr virus‐specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma , 1976, International journal of cancer.

[63]  H. Hausen,et al.  EB viral genomes in epithelial nasopharyngeal carcinoma cells. , 1973, Nature: New biology.

[64]  L. Old,et al.  PRECIPITATING ANTIBODY IN HUMAN SERUM TO AN ANTIGEN PRESENT IN CULTURED BURKITT'S LYMPHOMA CELLS* , 1966, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Pelayo Vilar,et al.  Nasopharyngeal Carcinoma , 1966 .